Spero Therapeutics' lead asset is an oral carbapenem tebipenem for cUTI. This asset achieved Phase 3 noninferiority. In fact, this data supports GSK’s NDA resubmission strategy. The prior FDA setback ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results